Long #ENLV above 18.50, COVID news#ENLV is in the news last week with regards to Covid-19 treatment.
I would be looking at the 18.46 area for a retest, and possible entry if we find support.
100% measured move would take the breakout to 23.81 and ultimately that would be my first target.
Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a longer term position and consider the 10.72-12.32 for a reentry.
Based on trend projection confluence and fib levels, id be looking to sell some shares at the 28.00 level
If we happen to see price action above these levels, i would consider targeting 37$ down the road.
The top of this trading range would be close to $45, Currently trading at 15.49
PHARMA
Aurobindo PharrmaThe stock has been in an uptrend and has taken an important support at its trendline in daily chart. It has been confirmed by forming bullish candlestick pattern called hammer at trendline support. One can go long by placing a stoploss of 889 and target can be 990. ( This is posted for education purpose only, Personal due diligence advised)
Psychedelics rally coming upBuy Case :
Increase demand for mental health services COVID indirect impact.
New and Innovative way of tackling depression and other mental health disorders and mental issues.
Correction from the high and expecting little consolidation around the price points mentioned in the chart
Any ideas and comments are welcomed!
Thanks in advance!
Together, we stand strong!
COHERUS cracking $21 will unleash major bullish potentialCOHERUS BIOSCIENCES Inc., NASDAQ:CHRS , is a bioscience company that has not yet not benefited from the sector's outperformance despite significantly improving financials and the business becoming profitable. When the stock price cracks the $21 level it will unlock a significant bullish potential.
Invest in the next scamThe chinese love powder made from endangered animals and trash plants , americans love their superfoods.
A plant called alfalfa (luzerne) that french farmers love to grow because it can get Nitrogen itself and it's cheap and packed with protein, they feed it to cattle, so to cows and also americans. Americans actually pay a high price to get supercheap leaves in powdered form.
Long gone are the days where scientists published a paper showing chicken like blondes more, to get average people interested in science, these days everyone is interested in science... And the result is quite amusing. Science has gotten politicised, the use of catchy words like "amazing" & "stunning" & "groundbreaking" in papers has grown 1000 fold (not even exagerating), there is a replication crisis, etc.
"Science" is the next big thing. I bet a study could show that when the average millenial sees the words "study shows" and "peer-reviewed" and "research suggests" he'll get a dopamine rush. Elon Musk sure cashed in on the "science & tech will save us all" large religious movement created by people abandonning the old religions.
Anything could happen, and nothing is too stupid. Dumb people think they are smart so it's a coinflip. For example we could go bet on homeopathy, try not to laugh while buying shares, but it can go either way. Lots of people are getting obsessed with health, this is a certainty. Several possibilities:
- "Conspiracy theorists", emboldened by sometimes being proven right when everyone calls them crazy and denies their claims, could believe in a conspiracy theory that expensive water is a valid medicament.
- "We're on the side of science" crowd, provided they hear some health authority or the media tell them so, will be 100% convinced homeopathy is a great super smart super science valid treatment.
- "We're on the side of science" crowd proudly claim homeopathy is pseudo-science and hurt the business, they could even ban it because it's "silly and no study shows and the WHO says"
If politicians decide the plebes take too much drugs (they do but the politicians take money from big pharma...) they could brainwash the "smart side of science non-conspiracy-theorists" clueless morons into buying water from scammy labs. It's just so hard not to laugh at the idea of people taking water medication.
You know, if they're going to be scared, and look for snakeoil superfoods and radioactive chemicals, might as well give them water, it won't hurt them.
It's actually a moral investment.
Other things could get big, how about "OMG study shows psilocybin cures depression let's all microdose mushrooms and also LSD because why not".
I heard "microdosing" was popular with tech executives as a magical boost to become smarter (AHEM!) and more productive.
Homeopathy... Mushrooms... Microdosing various lab-created drugs... Improvement microchips... Nanobots... We'll see what goes up. All of them?
The next bull cycle (50Y) is supposed to involve health. So this is important. Dumb irrealistic scams will, as always, go up way more (in %) than anything remotely legit.
People are unbelievably stupid, and it is getting worse, common sense is frowned upon, like literally, I can't believe this is real, you're a weirdo if you have common sense.
You cannot stop it. You can whine about it, or you can crack up and laugh hysterically while you take advantage of it for your own profit.
CXRXF Long IdeaCXRXF has been consolidating for a long time but now presents a low risk buy in. Notice the two trend lines, we are currently at the lower one. It could drop back 10% but I suspect even if it does, it will eventually drift towards the upper trend line. That's a nice 46% gain from here. Who knows, if it breaks the upper line it could really run.
Abbott India- FlagsPeople have written obituaries about this stock, as it is not moving since March 2020.
Stock has also closed below its 200 ema on a daily chart (which is generally considered bearish sign)
I may be wrong here, but what i see is stock is nicely moving in flag formation on a weekly chart. It is consolidating for now.
I will enter once that level breaks.
MASSIVE 200k Shares Buy On Order Book! (MDGS)Here we have a low float stock that recently popped past the all time Resistance channel from back in 2016.
Their is currently a massive order sitting to purchase 200k shares within the current price squeeze (triangle formation)
Lots of good news about this stock recently.
I like this setup and I personally think it will explode!
Hodl
Endo International Bullish News | Upside PotentialEndo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules.
According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. (Source: prnewswire.com)
Endo International plc (NASDAQ: ENDP) announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. (Source: newswire.ca)
"We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients," said Livio Di Francesco, Vice President and General Manager of Paladin.
Please leave me a message if you want to test the buy and sell indicators that i am using.
Big Pharma comparative analysis ---> a great time for them now ?Timestamp (black vertical line) : Mar 1 2020
---> Lockdowns worldwide due to Covid-19
- - - - - - - - - - - - - - - - - - - - - - - - - - -
GlaxoSmithKline plc ( GSK )
LSE:GSK
GlaxoSmithKline plc ( GSK ) is a British multinational pharmaceutical company headquartered in Brentford, England.
Price decrease of 9.50%
- - - - - - - - - - - - - - - - - - - - - - - - - - -
Sorrento Therapeutics Inc.
NASDAQ:SRNE
Sorrento Therapeutics , Inc. is a biopharmaceutical company. It is based San Diego (Calif.), USA
Price increase of 230%
- - - - - - - - - - - - - - - - - - - - - - - - - - -
As an ever greater number of companies seek to provide vaccines and enter the lucrative race of who will provide what
and who will be awarded plush government contracts, we can see that not all Big Pharma stocks are shining, pricewise.
Time will tell but if hindsight can teach us something, it is that whoever invested in this rather obscure and not well known company
called 'Sorrento Therapeutics", the investment would have been more rewarding than a comparable investment into GlaxoSmithKline plc .
Words of wisdom: if you have extra cash lying around, do a careful and thorough analysis first.
That is true, at all time, and even more so now, in this Covid-branded and forever altered world.
Francois Normandeau
Institutional Research Director for ADX-BRIEFING
P.S.
Live Stream on TradingView on Friday, January 1, 2021, at 6 am NY time, open to all.
See you there.
Big Pharma comparative analysis ---> a great time for them now ?Timestamp (black vertical line) : Mar 1 2020
---> Lockdowns worldwide due to Covid-19
- - - - - - - - - - - - - - - - - - - - - - - - - - -
GlaxoSmithKline plc (GSK)
LSE:GSK
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England.
Price decrease of 9.50%
- - - - - - - - - - - - - - - - - - - - - - - - - - -
Sorrento Therapeutics Inc.
NASDAQ:SRNE
Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is based San Diego (Calif.), USA
Price increase of 230%
- - - - - - - - - - - - - - - - - - - - - - - - - - -
As an ever greater number of companies seek to provide vaccines and enter the lucrative race of who will provide what
and who will be awarded plush government contracts, we can see that not all Big Pharma stocks are shining, pricewise.
Time will tell but if hindsight can teach us something, it is that whoever invested in this rather obscure and not well known company
called 'Sorrento Therapeutics", the investment would have been more rewarding than a comparable investment into GlaxoSmithKline plc.
Words of wisdom: if you have extra cash lying around, do a careful and thorough analysis first.
That is true, at all time, and even more so now, in this Covid-branded and forever altered world.
Francois Normandeau
Institutional Research Director for ADX-BRIEFING
P.S.
Live Stream on TradingView on Friday, January 1, 2021, at 6 am NY time, open to all.
See you there.
GoodRX - Possible bounceNot much history on this stock but with more potential lockdowns telemedicine seems like a buy to me. Testing my luck on this one. We have to at least bounce off support If it reaches $49-50 then we would have a cup and handle and target of $60-65 is possible.
However, nothing on this chart screams BUY to me. Sometimes you have to make dumb decisions to get dumb results.
Cipla - Short term pull back expected Cipla is showing negative divergences on a 15 minutes time frame.
Ideally, when price makes a new high and RSI fails to make a new high, it gives a good signal for a short term pullback.
However, pharma is in a strong bull rally, so entry and exit should be real quick.
Target 1 - 810
target 2 - 795
Sunpharma - Preparing for its Elliot wave 3Sun pharma is the biggest contributor in the Indian Pharma Index. So far, it has acted like a tired lion however, it seems the lion is ready to claim the kingship all over again.
Sun pharma has broken its 3-year downward trendline. RSI has already passed its complexion point.
It completed its corrective wave (2) at 450 levels around September. It is all set to touch 630, 750 & 800 levels.
800 would be a crucial level to watch and any correction from those levels will be another buying opportunity.